Biotech Stock News (RXII) (REGN) (SURG) (VRX) (ACAD)

Rxi Pharmaceuticals (NASDAQ:RXII) On August 31, 2015 Rxi announced that the 30-day review period for its IND of RXI-109 for scarring of macular degeneration has passed its review period and the IND is now active. The whole point of the 30-day review period is for the FDA to look at pre-clinical data and conclude whether … Read more

Biotech Stock News (ARWR)(AMGN)(ATHX)(PFE)

Arrowhead Research Corp (NASDAQ:ARWR) On April 13, 2015 Arrowhead announced that it was given the go-ahead by the FDA to begin treating patients in the phase 2b Hepatitis B study. ┬áThe drug compound being used in the study is known as ARC-520 which is an RNAi drug. RNAi stands for RNA interference and these types … Read more